1-Alkylpiperazinyl-Pyrrolidin-2,5-Dione Derivatives as Adrenergic Receptor Antagonists
申请人:Anand Nitya
公开号:US20070219216A1
公开(公告)日:2007-09-20
This invention relates to α
1a
and/or α
1d
adrenergic receptor antagonists of formula 1 Compounds disclosed herein can function as α
1a
and/or α
1d
adrenergic receptor antagonists and can be used for the treatment of diseases or disorders mediated through α
1a
and/or α
1d
adrenergic receptors. Compounds disclosed herein can be used for the treatment of benign prostatic hyperplasia and related symptoms thereof. Compounds disclosed herein can also be used for the treatment of lower urinary tract symptoms associated with or without benign prostatic hyperplasia. The invention also relates to a process for the preparation of compounds disclosed herein, pharmaceutical compositions containing these compounds and the methods of treating diseases or disorders mediated through α
1a
and/or α
1d
receptors.
[EN] METABOLITES OF 2-{3-[4-(2-ISOPROPOXYPHENYL) PIPERAZIN-1-YL]-PROPYL}-3A,4,7,7A-TETRAHYDRO-1H-ISOINDOLE-1,3-(2H)-DIONE<br/>[FR] METABOLITES DE LA 2-{3-[4-(2-ISOPROPOXYPHENYL)PIPERAZIN-1-YL]-PROPYL}-3A,4,7,7A-TETRAHYDRO-1H-ISOINDOLE-1,3-(2H)-DIONE
申请人:RANBAXY LAB LTD
公开号:WO2006092710A1
公开(公告)日:2006-09-08
[EN] The present invention relates to the metabolites of 2-3-[4-(2-isopropoxyphenyl) piperazin-1-yl]-propyl}-3a,4,7,7a -tetrahydro-1H-isoindole-1,3(2H)-dione of Formula I. The disclosed compounds can function as 1a-adrenoceptor antagonists and thus can be used for the treatment of benign prostatic hyperplasia (BPH) and related symptoms thereof. Processes for preparing the metabolites, pharmaceutical composition containing these metabolites and the method of treating BPH and related symptoms thereof are also provided. [FR] La présente invention concerne les métabolites de la 2-3-[4-(2-isopropoxyphényl)pipérazin-1-yl]-propyl}-3a,4,7,7a-tétrahydro-1H-isoindole-1,3(2H)-dione répondant à la formule I. Les composés décrits peuvent fonctionner en tant qu'antagonistes des récepteurs 1a-adrénergiques et peuvent donc être utilisés pour le traitement de l'hypertrophie bénigne de la prostate (HBP) et des symptômes apparentés. L'invention décrit également des procédés pour préparer les métabolites, une composition pharmaceutique contenant ces métabolites et le procédé de traitement de l'HBP et des symptômes apparentés.